Ongoing clinical trials

DETECT – An observational study to find out early, simple and reliable methods that can be used in the detection of pulmonary hypertension.

AIMSPRO – A study to find out if the drug AIMSPRO improves the quality of life in long standing diffuse scleroderma and to confirm that it is safe and well tolerated.

DISTOL – A study to find out the effect of a drug called treprostinil diethanolamine (UT-15C) on digital ulcers in patients with scleroderma.

DUO Register – This is a multi-centre prospective, observational study non-interventional programme to follow-up patients with digital ulcers over the course of the disease. The outcome of this study will inform on how to improve patient care in the long run.

ESOS – is an observational study investigating the effectiveness of currently used immunosuppressant therapies in early diffuse scleroderma scleroderma.

PISCES – A multi-centre randomised controlled trial to determine the efficacy of a simple pressure-relieving insole compared to a sham insole.

MYOSITIS – Identification of disease susceptibility genes associated with development and clinical characteristics of primary inflammatory muscle diseases, PM, DM and IBM.

PMI-CP200 (Medimmine Study) – To evaluate the safety and tolerability of escalating single IV doses of MEDI-551 in adult subjects with scleroderma who have at least moderate skin thickening in an area suitable for repeat biopsy. This is a Phase I “First time in man” study of a novel agent.

CAP – A multicenter, prospective cohort study using nail fold videoCAPillaroscopy (NVC) and other factors to determine the risk of developing digital ulceration in patients with systemic sclerosis (SSc).

SERAPHIN – This is a study to find out the effect of a drug called macitentan in pulmonary arterial hypertension.

FREEDOM STUDIES – These are studies to see the effect of UT-15C sustained release tablets in pulmonary arterial hypertension.

TADELAFIL – This is a study to evaluate the long term safety and efficacy of a drug called Tadelafil in the treatment of patients with pulmonary hypertension).

VOLT – This is a post marketing observational surveillance programme of a drug called Ambrisantan which is already licensed for treatment of PAH.

AMBITION – A study comparing the effect on time to clinical failure of initial combination therapy (ambrisentan and tadalafil) and initial monotherapy (ambrisentan or tadalafil) in subjects with pulmonary arterial hypertension.

CompERA – We are currently taking part in an international survey intended to obtain long term data on the different drugs that are used for treating pulmonary hypertension (high blood pressure in the lungs). All of these drugs have been approved throughout Europe for the treatment of high blood pressure in the lungs. However, it is not clear whether these drugs are really of equal value with regard to their effectiveness and tolerability. Therefore, we would like to document the progress of as many patients as possible who are being treated for pulmonary hypertension.

GRIPHON – A study evaluating a new drug, ACT-293987 for the treatment of pulmonary hypertension.

IMPRESS – This is a clinical trial evaluating the efficacy and safety of oral QTI571 (Imatinib) as an add-on therapy in the treatment of pulmonary hypertension.

PATENT – A study to assess the effectiveness and safety of different doses of a new drug (BAY-63-251, rociguat) given orally to patients with pulmonary hypertension.